Clinical trial
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
NCT00220727 · Grifols Therapeutics LLC, Industry · Completed
Key facts
| NCT number | NCT00220727 |
|---|---|
| Title | Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP |
| Official title | Randomized, Controlled, Open Study Investigating IGIV-C, 10% Given at Different Infusion Rates on Intravascular Hemolysis in Patients With Idiopathic (Immune) Thrombocytopenic Purpura (ITP) |
| Lead sponsor | Grifols Therapeutics LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Purpura, Thrombocytopenic, Idiopathic |
| Intervention type | Drug |
| Interventions | Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified |
| Enrollment | 8 |
| Start date | Jul 1, 2003 |
| Primary completion | Oct 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 27, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: